Veteran drug discovery leader joins to help advance innovative treatments for autoimmune and inflammatory diseases.
Odyssey Therapeutics, a clinical-stage biopharmaceutical company focused on redefining treatment approaches for autoimmune and inflammatory diseases, has announced the appointment of renowned drug discovery expert H. Martin Seidel, Ph.D., to its Scientific Advisory Board. The move reflects the company’s commitment to strengthening its scientific leadership as it advances a growing pipeline of therapies designed to precisely target the underlying biological mechanisms that drive complex immune-mediated disorders.
Strengthening Scientific Leadership at a Critical Growth Stage
The addition of Dr. Seidel to the advisory board comes at an important time for Odyssey Therapeutics as it continues to expand its research programs and move several of its most promising therapies closer to clinical development. The company is dedicated to transforming the standard of care for patients living with autoimmune and inflammatory conditions by developing innovative medicines that address the root causes of disease rather than simply managing symptoms.
By bringing Dr. Seidel into its circle of scientific advisors, Odyssey gains the benefit of decades of expertise in translating cutting-edge biological discoveries into meaningful drug development programs. His experience across biotechnology startups and major pharmaceutical organizations positions him to provide valuable strategic guidance as the company identifies new therapeutic targets and advances them toward the clinic.
A Career Spanning Biotechnology Innovation and Global Pharmaceutical Leadership
Dr. Seidel is widely recognized as an accomplished leader in drug discovery and development. Over the course of his career, he has contributed to numerous scientific and strategic initiatives that have shaped the development of novel therapies across multiple disease areas.
He currently serves as Chief Executive Officer of IFM Therapeutics, a biotechnology company known for pioneering research in innate immunity and inflammation. Under his leadership, IFM Therapeutics has successfully advanced multiple discovery and development programs while also achieving three notable portfolio company exits, underscoring the company’s ability to translate promising scientific insights into commercially viable therapeutic opportunities.
Before joining IFM Therapeutics, Dr. Seidel spent more than a decade at the Novartis Institutes for Biomedical Research, the global research arm of Novartis. During his tenure there, he held several senior leadership positions that placed him at the forefront of pharmaceutical innovation and collaborative research.
Among his most prominent roles was serving as Head of the Genomics Institute of the Novartis Research Foundation, a leading research institute dedicated to applying genomic technologies to accelerate drug discovery. In that capacity, he oversaw multidisciplinary teams working to uncover new disease targets and translate genomic insights into therapeutic strategies.
Dr. Seidel also served as Global Head of Business Development and Licensing at Novartis, where he played a central role in shaping the company’s external innovation strategy. In this position, he was responsible for identifying and managing strategic partnerships, collaborations, and licensing agreements designed to bring promising technologies and research programs into the Novartis pipeline.
His leadership in these roles helped advance numerous discovery programs into clinical development, while also fostering collaborations that bridged academic science and pharmaceutical innovation.
Translating Scientific Discovery into Clinical Impact
One of Dr. Seidel’s defining strengths throughout his career has been his ability to translate groundbreaking scientific research into viable drug development programs. His work has spanned the entire drug discovery and development process—from target identification and validation to portfolio strategy and translational decision-making.
Across multiple therapeutic areas, he has played an influential role in guiding research teams toward programs that ultimately progressed into clinical trials and, in some cases, approved medicines. This combination of scientific expertise and strategic insight is particularly valuable for emerging biotechnology companies seeking to bring innovative therapies to patients.
For Odyssey Therapeutics, Dr. Seidel’s experience will help support the company’s efforts to identify high-value targets in immunology and inflammation biology. His guidance is expected to strengthen the scientific framework that underpins the company’s research programs while helping ensure that promising discoveries are effectively translated into clinical candidates.
Confidence from Odyssey’s Leadership Team
Gary D. Glick, Ph.D., Founder and Chief Executive Officer of Odyssey Therapeutics, emphasized that Dr. Seidel’s appointment reflects both his scientific reputation and his longstanding professional relationships with members of the company’s leadership team.
According to Glick, Dr. Seidel brings exceptional depth of knowledge in drug discovery, translational science, and portfolio strategy. Several members of Odyssey’s scientific leadership have worked with him previously, creating a foundation of trust and shared experience that the company believes will strengthen its research efforts.
Glick noted that this existing collaboration includes scientists such as Dennis Dean, Ph.D., Luigi Franchi, M.D., Ph.D., Tony Opipari, M.D., Ph.D., and Bill Roush, Ph.D. Their collective experience working with Dr. Seidel has given the leadership team confidence in his ability to help guide Odyssey’s scientific strategy during a pivotal stage of growth.
Glick also highlighted the importance of Dr. Seidel’s perspective, shaped by decades of advancing programs across diverse scientific platforms. As Odyssey continues to expand its pipeline and refine its approach to drug discovery, that perspective is expected to play a key role in helping the company prioritize targets and navigate complex scientific decisions.
Dr. Seidel’s Perspective on Odyssey’s Scientific Vision
Dr. Seidel expressed enthusiasm about joining the company’s Scientific Advisory Board, noting that Odyssey Therapeutics is operating in an area of biology that is particularly promising for new drug discovery.
He emphasized that the breadth of scientific capabilities assembled by the company’s team stands out within the current biotechnology landscape. In his view, this integrated approach—combining deep biological insight with innovative discovery technologies—creates a powerful foundation for developing new treatments for immune-related diseases.
Having previously collaborated with several members of Odyssey’s scientific leadership team, Dr. Seidel also noted that he has developed a strong appreciation for their rigorous approach to science and their ambition to push the boundaries of therapeutic innovation.
He believes his experience in target selection, translational research, and drug development strategy will complement the company’s ongoing efforts to bring new therapies into the clinic.
The Role of the Scientific Advisory Board
Odyssey Therapeutics’ Scientific Advisory Board plays a critical role in shaping the company’s research direction. The board is composed of leading experts in immunology, inflammation biology, and therapeutic development who provide strategic insight and scientific oversight.
By drawing on the expertise of these advisors, the company aims to ensure that its discovery programs remain grounded in the latest scientific advances while also maintaining a clear path toward clinical translation.
With the addition of Dr. Seidel, the advisory board gains another distinguished voice with extensive experience in both scientific innovation and pharmaceutical strategy.